• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC HEART VALVES DIVISION MEDTRONIC SURGICAL TISSUE VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC HEART VALVES DIVISION MEDTRONIC SURGICAL TISSUE VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Model Number MDT-TISSUE VALVE
Device Problems Perivalvular Leak (1457); Device Stenosis (4066); Central Regurgitation (4068)
Patient Problems Aortic Valve Stenosis (1717); Non specific EKG/ECG Changes (1817); Endocarditis (1834); Hemorrhage/Bleeding (1888); Pseudoaneurysm (2605); Heart Failure/Congestive Heart Failure (4446); Valvular Insufficiency/ Regurgitation (4449); Mitral Valve Insufficiency/ Regurgitation (4451)
Event Date 06/01/2023
Event Type  Injury  
Manufacturer Narrative
Citation: tomsic et al.Extensive aortic root endocarditis with extension into the intervalvular fibrous body: an updated report of a mitral valve sparing approach.Eur j cardiothorac surg.2023 jun 1;63(6):ezad114.Doi: 10.1093/ejcts/ezad114.Earliest date of publication used for date of event.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Literature was reviewed regarding extensive aortic root endocarditis with extension into the intervalvular fibrous body. the study population included 60 patients who were predominantly male with a mean age of 61 years.  multiple manufacturer¿s devices were implanted in the study population; 42 patients were implanted with a medtronic freestyle bioprosthetic aortic root (n=37), hancock ii aortic bioprosthetic valve (n=1) or simulus annuloplasty ring (n=4) for mitral valve repair. deaths occurred in the study population; however, there was no statement establishing a causal or contributory relationship between medtronic product and the deaths.  among all patients adverse events included: infective endocarditis, bleeding complication, paravalvular leak, mitral regurgitation, pseudoaneurysm, arrhythmia requiring permanent pacemaker implant, congestive heart failure, moderate valvular stenosis, acute kidney injury, and re-intervention some of which required mechanical circulatory support with extracorporeal membrane oxygenation or intra-aortic balloon pump. no further information pertaining to medtronic products was noted.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MEDTRONIC SURGICAL TISSUE VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer (Section G)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key17961743
MDR Text Key326005918
Report Number2025587-2023-04223
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeNL
PMA/PMN Number
P970031
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature
Reporter Occupation Physician
Type of Report Initial
Report Date 10/18/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/18/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberMDT-TISSUE VALVE
Device Catalogue NumberMDT-TISSUE VALVE
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received10/05/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Life Threatening; Required Intervention; Hospitalization;
Patient Age61 YR
Patient SexMale
-
-